Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Eugénie Bassères"'
Autor:
Ximena Cortes-Bratti, Eugénie Bassères, Fabiola Herrera-Rodriguez, Silvia Botero-Kleiven, Giuseppe Coppotelli, Jens B Andersen, Maria G Masucci, Arne Holmgren, Esteban Chaves-Olarte, Teresa Frisan, Javier Avila-Cariño
Publikováno v:
PLoS ONE, Vol 6, Iss 2, p e16960 (2011)
BackgroundThioredoxin 80 (Trx80) is an 80 amino acid natural cleavage product of Trx, produced primarily by monocytes. Trx80 induces differentiation of human monocytes into a novel cell type, named Trx80-activated-monocytes (TAMs).Principal findingsI
Externí odkaz:
https://doaj.org/article/a3a2c7311ab8442e9881fec7e662edd7
Autor:
Mark H. Wilcox, Eugénie Bassères, David W Eyre, Khurshida Begum, Anne J Gonzales-Luna, Tasnuva Rashid, Chris Lancaster, Travis J Carlson, M. Jahangir Alam, Kevin W. Garey, Julie Miranda
Publikováno v:
Journal of Antimicrobial Chemotherapy
Background Eravacycline is a novel synthetic fluorocycline antibacterial approved for complicated intra-abdominal infections. Objectives The purpose of this study was to assess the in vitro activities of eravacycline and comparator antibiotics agains
Publikováno v:
Expert Opinion on Investigational Drugs. 28:303-310
Ridinilazole is a novel antibiotic being developed for the treatment of Clostridioides difficile infection (CDI). Ridinilazole has completed two phase II trials and phase III trials which are denoted Ri-CoDIFy 1 and 2, are planned (ClinicalTrials.gov
Autor:
Khurshida Begum, Nicolás Montes-Bravo, Nicolás Pérez-Soto, Daniel Paredes-Sabja, M. Jahangir Alam, Bradley T. Endres, Christopher K Lancaster, Tasnuva Rashid, Kevin W. Garey, Eugénie Bassères
Publikováno v:
Anaerobe. 69
Indexación Scopus Background: Fidaxomicin has novel pharmacologic effects on C. difficile spore formation including outgrowth inhibition and persistent spore attachment. However, the mechanism of fidaxomicin attachment on spores has not undergone ri
Autor:
Kevin W. Garey, Julie Miranda, Travis J Carlson, Khurshida Begum, Eugénie Bassères, M. Jahangir Alam, Anne J Gonzales-Luna, David W Eyre, Tasnuva Rashid, Chris Lancaster, Mark H. Wilcox
Publikováno v:
Antimicrobial Agents and Chemotherapy
Omadacycline is a potent aminomethylcycline with in vitro activity against Gram-positive, Gram-negative, and anaerobic bacteria. Preliminary data demonstrated that omadacycline has in vitro activity against Clostridioides difficile; however, large-sc
Autor:
Khurshida Begum, Julie Le Pham, Faris S Alnezary, Travis J Carlson, Eugénie Bassères, M. Jahangir Alam, Anne J Gonzales-Luna, Kevin W. Garey, Bradley T. Endres, Kimberly Nebo, Kelly R. Reveles, Chris Lancaster, Julie Miranda
Publikováno v:
Open Forum Infectious Diseases
Background Patients with Clostridioides difficile infection (CDI) with either eosinopenia or infected with a binary toxin strain have increased likelihood of mortality. However, the relationship between binary toxin and eosinopenia to synergistically
Autor:
Shawn Tupy, Kevin W. Garey, Sandi Arnold, Kierra M Dotson, Khurshida Begum, Conner Carlsen, Christa Cook, Jacob G. McPherson, Kelley Poblete, Chris Lancaster, M. Jahangir Alam, Bradley T. Endres, Ali Memariani, Eugénie Bassères, Bonnie Morehead, Sophia Anyatonwu
Publikováno v:
Infection Control & Hospital Epidemiology. 39:1322-1329
ObjectiveThis article describes a CDI outbreak in a long-term care (LTC) facility that used molecular typing techniques and whole-genome sequencing to identify widespread dissemination of the clonal strain in the environment which was successfully re
Autor:
Tasnuva Rashid, Herbert L. DuPont, Kevin W. Garey, Eugénie Bassères, Shreela V. Sharma, Irtiza Hasan, M. Jahangir Alam, Farnoosh Haghighi, Dejian Lai
Publikováno v:
Antimicrob Agents Chemother
Clostridioides difficile spores can survive in the environment in either mono- or mixed-species biofilms. However, no previous studies have investigated chemical disinfection of C. difficile spores embedded in biofilms. Thus, the purpose of this stud
Autor:
Jennifer M. Auchtung, Qinglong Wu, Kevin W. Garey, Amy C. Engevik, Mary K. Estes, Sue E. Crawford, Ruth Ann Luna, Tor C. Savidge, Heather A. Danhof, Wenly Ruan, James Versalovic, Maribeth R Nicholson, Eugénie Bassères, Mary Beth Yacyshyn, Renate Lux, Bradley T. Endres, Bruce R. Yacyshyn, Robert A. Britton, Melinda A. Engevik
Publikováno v:
Gastroenterology
Background & Aims Although Clostridioides difficile infection (CDI) is known to involve the disruption of the gut microbiota, little is understood regarding how mucus-associated microbes interact with C difficile. We hypothesized that select mucus-as
Publikováno v:
Current Opinion in Gastroenterology. 33:1-7
PURPOSE OF REVIEW Clostridium difficile infections (CDI) remain a challenge to treat clinically due primarily to limited number of antibiotics available and unacceptably high recurrence rates. Because of this, there has been significant demand for cr